EntreMed, a  Washington   DC- area biotech, has filed an application with the SFDA to begin clinical trials in  China  of its cancer treatment, ENMD-2076. The trial is a US-China Phase II test of the drug in patients with triple-negative breast cancer. EntreMed said that adding a  China  arm to the trial would shorten the time necessary for patient recruitment and save on other costs as well. More details.... Stock Symbol: (NSDQ: ENMD) Share this with colleagues: // //